Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd) (wCCyd)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01857115
Recruitment Status : Active, not recruiting
First Posted : May 20, 2013
Last Update Posted : August 2, 2018
Sponsor:
Collaborator:
Fondazione Neoplasie Sangue Onlus
Information provided by (Responsible Party):
Stichting Hemato-Oncologie voor Volwassenen Nederland

Brief Summary:
This protocol is a phase I/II multicenter study designed to assess the safety and the efficacy of the proposed combinations as up-front treatment in elderly Multiple Myeloma (MM) patients.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: Carfilzomib Drug: Cyclophosphamide Drug: Dexamethasone Phase 1 Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A MULTICENTER, OPEN LABEL STUDY OF WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (wCCyd) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS
Actual Study Start Date : April 2013
Actual Primary Completion Date : November 2013
Estimated Study Completion Date : April 2019


Arm Intervention/treatment
Experimental: CCyd

Treatment schedule for 9 cycles of induction:

  1. Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15.
  2. Dexamethasone given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23.
  3. Carfilzomib given 20 mg/m2 IV once daily on Day 1 of Cycle 1 only followed by 36/45/56/70 mg/m2 on days 8, 15 of Cycle 1, then for all subsequent doses 70 mg/m2 IV once daily on days 1, 8, 15, followed by 14-day rest period (day 16 through 28).

Treatment schedule for maintenance until progression or intolerance:

Carfilzomib at the MTD defined by phase I study IV once daily on days 1, 8, 15.

Drug: Carfilzomib
Other Name: Krypolis

Drug: Cyclophosphamide
Other Name: Endoxan

Drug: Dexamethasone
Other Name: Decadron




Primary Outcome Measures :
  1. Identification of Dose-limiting toxicity (DLT) [ Time Frame: 1 year ]

    Non-hematologic:

    • Grade2 neuropathy with pain
    • any Grade 3 toxicity (excluding nausea, vomiting, diarrhea)
    • Grade3 nausea, vomiting, or diarrhea despite maximal antiemetic/antidiarrheal therapy
    • Grade4 fatigue lasting for ≥7days

      • Any non-hematologic toxicity requiring a dose reduction within Cycle1
      • Inability to receive Day 1 dose of Cycle2 due to drug related toxicity persisting from Cycle1 or drug related toxicity newly encountered on Day1 of Cycle2.

    Hematologic:

    • Grade 4 neutropenia (ANC<0.5x109/L) lasting for ≥7days
    • Febrile neutropenia (ANC<1.0x109/L with a fever ≥38.3ºC)
    • Grade 4 thrombocytopenia (platelets<25.0x109/L) lasting ≥7 days despite dose delay
    • Grade 3-4 thrombocytopenia associated with bleeding
    • Any hematologic toxicity requiring a dose reduction within Cycle1
    • Inability to receive Day1 dose of Cycle2 due to drug related toxicity persisting from Cycle1 or drug related toxicity newly encountered on Day1 of Cycle2.

  2. Partial Response (PR) [ Time Frame: 1 year ]
    The primary efficacy endpoints will be assessed by considering partial response (PR) following the proposed regimen, at the end of third cycle.


Secondary Outcome Measures :
  1. Response rate (RR) [ Time Frame: 3 years ]
    Determine the response rate

  2. Progression free-survival (PFS) [ Time Frame: 3 years ]
    Determine progression free-survival

  3. Time to progression (TTP) [ Time Frame: 3 years ]
    Determine the time to progression

  4. Duration of response (DOR) [ Time Frame: 3 years ]
    Determine the duration of response

  5. Overall survival (OS) [ Time Frame: 3 years ]
    Determine the overall survival

  6. Time to next therapy (TTNT) [ Time Frame: 3 years ]
    Determine the time to next therapy

  7. Responses [ Time Frame: 3 years ]
    Determine whether responses obtained with wCCyd treatment are associated with a prolongation of PFS, in comparison with non-responding patients

  8. Response and survival [ Time Frame: 3 years ]
    Determine whether tumor response and survival might significantly change in particular subgroups of patients defined on prognostic factors (β2-microglobulin, C-reactive protein (CRP), FISH, gene expression profile)

  9. Maintenance [ Time Frame: 3 years ]
    • Determine the benefit on PFS and OS of maintenance with Carfilzomib
    • Determine the benefit on tumor load of maintenance with Carfilzomib



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 99 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Disease-related

  1. Patient is a newly diagnosed MM patient.
  2. Patient is age ≥ 65 year of age or who are ineligible for autologous stem cell transplantation.
  3. Patient has measurable disease, defined as follows: any quantifiable serum monoclonal protein value (generally, but not necessarily, ≥ 0.5 g/dL of M-protein) and, where applicable, urine light-chain excretion of > 200 mg/24 hours. For patients with oligo- or non-secretory MM, it is required that they have measurable plasmacytoma > 2 cm as determined by clinical examination or applicable radiographs (i.e. MRI, CT-Scan) or an abnormal free light chain ratio (n.v.: 0.26-1.65). We anticipate that less than 10% of patients admitted to this study will be oligo- or non-secretory MM with free light chains only in order to maximize interpretation of benefit results.

    Demographic:

  4. Age ≥ 18 years.
  5. Life expectancy ≥ 3 months.
  6. Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (Appendix F).

    Laboratory:

  7. Adequate hepatic function, with serum ALT ≤ 3.5 times the upper limit of normal and serum direct bilirubin ≤ 2 mg/dL (34 µmol/L) within 14 days prior to randomization.
  8. Absolute neutrophil count (ANC) ≥ 1.0 × 109/L within 14 days prior to randomization.
  9. Corrected serum calcium ≤ 14 mg/dL (3.5 mmol/L).
  10. Alanine transaminase (ALT): ≤ 3 x the ULN.
  11. Hemoglobin ≥ 8 g/dL (80 g/L) within 14 days prior to randomization (subjects may be receiving red blood cell [RBC] transfusions in accordance with institutional guidelines).
  12. Platelet count ≥ 50 × 109/L (≥ 30 × 109/L if myeloma involvement in the bone marrow is > 50%) within 14 days prior to randomization.
  13. Creatinine clearance (CrCl) ≥ 15 mL/minute within 7 days prior to randomization, either measured or calculated using a standard formula (eg, Cockcroft and Gault).

    Ethical/Other:

  14. Written informed consent in accordance with federal, local, and institutional guidelines.
  15. Females of childbearing potential (FCBP) must agree to ongoing pregnancy testing and to practice contraception.
  16. Male subjects must agree to practice contraception.

Exclusion Criteria:

Disease-related:

  1. Previous treatment with anti-myeloma therapy (does not include radiotherapy, bisphosphonates, or a single short course of steroid; ≤ to the equivalent of dexamethasone 40 mg/day for 4 days)
  2. Patient with relapsed or refractory multiple myeloma.
  3. Patients with non-secretory MM unless serum free light chains are present and the ratio is abnormal.

    Concurrent Conditions:

  4. Pregnant or lactating females (Appendix I).
  5. Major surgery within 21 days prior to randomization.
  6. Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to randomization.
  7. Known human immunodeficiency virus infection.
  8. Active hepatitis B or C infection.
  9. Unstable angina or myocardial infarction within 4 months prior to randomization, NYHA Class III or IV heart failure, uncontrolled angina, history of severe coronary artery disease, severe uncontrolled ventricular arrhythmias, sick sinus syndrome, or electrocardiographic evidence of acute ischemia or Grade 3 conduction system abnormalities unless subject has a pacemaker.
  10. Uncontrolled hypertension, uncontrolled congestive heart failure (CHF) or uncontrolled diabetes within 14 days prior to randomization.
  11. Non-hematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas.
  12. Significant neuropathy (Grades 3-4, or Grade 2 with pain) within 14 days prior to randomization.
  13. Known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).
  14. Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to all anticoagulation and antiplatelet options, antiviral drugs, or intolerance to hydration due to preexisting pulmonary or cardiac impairment.
  15. Subjects with pleural effusions requiring thoracentesis or ascites requiring paracentesis within 14 days prior to randomization.
  16. Any other clinically significant medical disease or condition that, in the Investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01857115


Locations
Layout table for location information
Italy
FO.NE.SA.Onlus
Torino, Italy, 10126
Sponsors and Collaborators
Stichting Hemato-Oncologie voor Volwassenen Nederland
Fondazione Neoplasie Sangue Onlus

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Stichting Hemato-Oncologie voor Volwassenen Nederland
ClinicalTrials.gov Identifier: NCT01857115     History of Changes
Other Study ID Numbers: IST-CAR-561
First Posted: May 20, 2013    Key Record Dates
Last Update Posted: August 2, 2018
Last Verified: August 2018

Keywords provided by Stichting Hemato-Oncologie voor Volwassenen Nederland:
Multiple myeloma
Diagnosis
Weekly
CCyd

Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone
Dexamethasone acetate
Cyclophosphamide
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Protease Inhibitors